Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-647

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Retrospective review of patients with recurrent glioblastoma multiforme (GBM) treated with ipilimumab)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Retrospective Chart Review GBM

To Learn More Call
201-510-0910

Neuro-Oncology Database

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC Neuro-Oncology Database (Kaptain)

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)